Health Canada will begin a rolling review of efficacy and safety data from Quebec-based Medicago’s late-stage COVID-19 vaccine trial. Rolling reviews allow data to accepted on an on-going basis while a trial is still underway. The company is making its plant-based vaccine in partnership with GlaxoSmithKline, who are producing a booster for it. Data from a mid-stage trial will be reported in full by the end of April. Medicago’s vaccine is widely seen as the most advanced Canadian candidate.